Evidence map›Paper›PMID 41533016›Full record

ArticleMolecular diversity2026

Design, synthesis, and biological evaluation of quinoxalinyl and quinolinyl derivatives as ALK5 inhibitors.

Chuang Liu, Jun Li, Yu-Qi Lu, Yu-Xin Jiang, Cheng-Hua Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chuang Liu *Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, China.
Jun Li *Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, China.
Yu-Qi LuKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, China.
Yu-Xin JiangKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, China.
Cheng-Hua JinKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, China. jinchenghua@ybu.edu.cn.

Funding

Natural Science Foundation of Jilin Province YDZJ202201ZYTS547
6 · The paper itself

Abstract

Six series of ether (14a-i and 15a-i), ester (17a-f and 18a-f) and amine derivatives (21a and 22a-g) containing quinoxalinyl and quinolinyl moieties were synthesized and evaluated for their inhibitory activities against activin receptor-like kinase 5 (ALK5). Among all the compounds, compound 22f (IC

Indexed as

Drug DesignProtein Kinase InhibitorsQuinolinesQuinoxalinesReceptor, Transforming Growth Factor-beta Type IHumansStructure-Activity RelationshipProtein Kinase InhibitorsQuinolinesQuinoxalinesReceptor, Transforming Growth Factor-beta Type ITGFBR1 protein, humanALK5 inhibitorAminePyrazoleQuinolineQuinoxaline

Identifiers

PMID41533016

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.